Connect to other sites within the UBM Medica Network
It has long been understood that MI may increase the risk of atrial fibrillation. A study in JAMA-Internal Medicine now finds that that the opposite relationship may also be true.
Genotype-guided Warfarin Dosing: Does it Improve TTR?
In clinical scenarios where warfarin is still the drug of choice for anticoagulation it is still a challenge to achieve optimal time in therapeutic range. Is there promise in a new dosing paradigm?
Complex LAA Shape Predicts Thromboembolic Risk
Results of a Japanese study suggest that number of LAA lobes may one day be useful as an element of the CHADS2 scoring system for embolic risk in patients with atrial fibrillation.
RE-LY AF Registry: Hypertension Most Common Risk Factor Worldwide
Comprised of 15 400 patients from 46 countries, the RE-LY AF registry offers a notable opportunity to study variations in presentation of atrial fibrillation and its risk factors.
In Dialysis Patients with Atrial Fibrillation, Anticoagulation Offers No Benefit
In dialysis patients, anticoagulation for AF may be cause for clinical equipoise, regardless of bleeding risk score. New research, reported here, may begin to shift the balance.
Caffeine and Atrial Fibrillation: Is There a Protective Effect?
A lot of conflicting data have emerged about the health effects of caffeine consumption that suggest it may actually be beneficial for health.
Atrial Fibrillation: Bad for the Heart and the Soul
An observational study of patients with atrial fibrillation suggests that routine screening for depression at office visits may help augment treatment.
Atrial Fibrillation and Myocardial Infarction: A Two-Way Street?
A new study provides more evidence of important bidirectional relationships between AF and other cardiovascular comorbidities.
Women and Heart Disease: Incidence, Prevalence, Progress, and the Future
Female CV mortality lags behind male mortality; lifetime risk assessment, not 10-year risk, is a better estimation tool for women
The Great Beta-Blocker Debate: The Pros and Cons
Newly diagnosed hypertension in a patient whose blood pressure is 152/94 mm Hg. What agents will you consider for this patient? Beta-blockers? Think again.
AHA 2012 Highlights: Multivitamins, Omega-3s, the Polypill, and More
Platelet function monitoring and adjustment of treatment based on results after coronary stenting does not improve clinical outcomes . . . and other findings from the AHA Scientific Sessions.
Who Needs Beta-Blockers? Analysis Raises Questions
A new analysis of data from a large international registry finds that use of beta-blockers in patients with and without a history of coronary artery disease does not reduce cardiovascular events.